Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Follicular 3Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Leukemia 2Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1

Interventions

Rituximab 14pirtobrutinib 6ibrutinib 4Vincristine 4Doxorubicin 4Prednisone 3Cytarabine 3Cyclophosphamide 3zanubrutinib 2acalabrutinib 2Methotrexate 2Etoposide 2Bendamustine Hydrochloride 2venetoclax 1tositumomab I-131 1idelalisib 1ibritumomab tiuxetan 1etoposide phosphate 1entecavir 1cirmtuzumab 1axicabtagene ciloleucel 1VAP-cyclo protocol 1Tenofovir 1Radiotherapy 1Melphalan 1Ifosfamide 1Gemcitabine 1Everolimus 1Drug Therapy 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, B-Cell × idelalisib × Clear all
NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡